Dr. Lunning on Initial Treatment Considerations in CLL

Publication
Video
Supplements and Featured PublicationsMy Treatment Approach: Chronic Lymphocytic Leukemia
Volume 1
Issue 1

Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.

Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses initial treatment considerations in chronic lymphocytic leukemia (CLL).

Patients with CLL often present with asymptomatic disease that is identified with a routine complete blood count, Lunning explains.

To confirm a CLL diagnosis, patients typically undergo flow cytometry on peripheral blood, says Lunning. Afterward, a lymphocyte count, hemoglobin count, and platelet count should be conducted.

Additionally, patients should have a physical exam to identify splenomegaly, concerning adenopathy, or irregular lymph nodes, Lunning explains.

Richter’s transformation indicates a poorer prognosis and can significantly alter a patient’s treatment in the newly diagnosed or relapsed/refractory setting, concludes Lunning.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD